RE: Slowly, slowly .....10 May 2021 21:18
Roobler - I found this in today’s RNS attachment. I’m not totally sure but it seems that we do still have some benefit from iclaprim if it ever creates revenue above the amount shown below.
“14. Subsequent events
In January 2021, the Company divested the ownership of Motif Biosciences, Inc. to Orange Avenue Technologies, LLC ('Orange'), an entity controlled by John Palmer of Tamarack Associates Inc. Mr. Palmer, through Tamarack Associates Inc., was previously appointed in early 2020 as the sole Executive Officer of Motif BioSciences. Under the Stock Purchase Agreement with Orange, the Company will receive 90% of the revenues received by Inc. from iclaprim, above a $250,000 threshold.”
I’m not a legal guy so whether this lapses or continues when the new company is formed is anyone’s guess. But I feel, this condition was meant to protect our ‘failed’ drug from being lost forever from those that fought hard to monetise it. This drug has a long history and for sure is not the last time someone tries to get it approved. It will happen one day. For now though we should park this and look forward to the ‘new’ team and their business plans and products. Rather exciting!
GS